VelaLabs was founded as “Vela pharmazeutische Entwicklung und Laboranalytik GmbH” as a management buy out end of 2006 and took over analytic and infrastructure of the former Novartis spin off Ingeneon.
From the beginning it has specialized in the characterization of biologics and early realized the potential of biosimilars.
In 2007, VelaLabs was GMP-certified and implemented GCLP rules in 2009 to be able to conduct the sample analysis of clinical studies according to relevant guidelines.
- 2011: first batch release testing of clinical material
- 2014: first market material (G‑CSF)
- 2019: registered at the FDA
- 2020: GLP certification
- 2020: Acquistion of LABH (Labor für Betriebshygiene), building a new clean room for sterility testing under GMP conditions
In 2016 Tentamus group – internationally positioned with more than 90 laboratories in 23 countries – acquired VelaLabs, perfectly fitting into the group’s ‘closer-to-the-customer’ strategy based on local labs covering the full service portfolio along the chain of custody.
Until today VelaLabs introduced further analytical services such as ECL technology (MesoScaleDiscovery), being part of a PBMC network and a cell based assay cooperation, as well as latest equipment for SPR testing, and multi label reader with qualified evaluation software.
The team grew to over 80 employees until 2022.
Share our vision of meaningful analytics to support medication development.
Innovation, flexibility, and performance of our analytics ensure product safety and it is our contribution to a healthier life.